Zylox-Tonbridge has finalized the acquisition of Optimed, a Germany-based medical technology company, in a transaction valued at €87 million. The move expands Zylox-Tonbridge’s footprint in advanced diagnostic imaging and positions it for stronger growth in European healthcare markets.
- Zylox-Tonbridge acquired Optimed GmbH for €87 million in cash.
- Optimed generated €34 million in revenue in 2025 and holds three FDA/CE-approved devices.
- ZT shares rose 4.7% post-announcement; OPTM shares surged 18%.
- Integration expected to increase Zylox-Tonbridge’s R&D output by 22% over two years.
- New sub-brand ZT-Optimed to focus on AI-enhanced surgical imaging.
- Regulatory approvals secured in both the UK and Germany.
Zylox-Tonbridge, a U.K.-traded medical devices firm listed under ticker ZT, has completed its acquisition of Optimed GmbH, a specialized German developer of precision diagnostic imaging systems. The all-cash deal, totaling €87 million, was announced on January 19, 2026, marking one of the most significant cross-border M&A activities in the European medtech sector this year. Optimed, headquartered in Munich, specializes in AI-driven intraoperative imaging platforms used in neurosurgery and orthopedic procedures. The acquisition is strategically designed to accelerate Zylox-Tonbridge’s innovation pipeline. Optimed’s portfolio includes three FDA-cleared and CE-marked devices, with projected annual revenue of €34 million in 2025. Integration of these technologies into Zylox-Tonbridge’s existing surgical robotics division is expected to boost R&D output by 22% over the next two years. The combined entity will operate under a new sub-brand, ZT-Optimed, focusing on high-margin, digitally enhanced surgical tools. Market reaction has been positive: Zylox-Tonbridge shares rose 4.7% in early trading following the announcement, while Optimed’s former parent entity, OPTM, saw its pre-acquisition shares surge 18% on investor optimism about exit value. Analysts note that the deal strengthens Zylox-Tonbridge’s competitive edge against global rivals such as Medtronic and Stryker in the premium surgical imaging niche. The transaction is subject to final regulatory clearance in Germany and the UK, both of which were obtained without conditions. Industry observers expect the integration to be complete by Q3 2026.